Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OKYO
Strong SellSinkerOKYO Pharma Limited · Healthcare · United Kingdom · $88M · Avg Vol: $102K/d
4
StockRankGet insider-trade alerts
Q
24
V
24
M
23
P/E (TTM)
—
ROE
-263.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 11.0M | — |
| EPS | — | -0.61 | -0.57 | -0.12 | -0.24 | — | -0.24 | -0.12 | -0.66 | — |
| Shares | — | 51.0M | 33.3M | 36.0M | 52.5M | +2.8% | 52.5M | — | — | — |
| Debt | 0 | 2.2M | — | — | — | — | — | — | — | — |
| Equity | — | -2.1M | -5.9M | -5.5M | 12.3M | — | — | — | — | — |
| Op CF | — | -7.7M | -9.5M | -1.8M | -5.9M | — | -5.9M | — | — | — |
| Inv CF | — | -5.9K | 0 | -1.2K | -6.0M | — | — | — | — | — |
| Fin CF | — | 9.3M | 6.2M | 2.7M | 25.0M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-13.9%
SMA 50SMA 200
Close
$1.43
RSI (14)
44.0
52W High
$3.20
From 52W High
0.4%
SCORE BREAKDOWN
Quality
24
ROIC
-68.6%10.6
ROE
-263.8%3.1
GP/Assets
-31.9%2.6
Op. Margin
0.0%38.1
FCF/Assets
-28.3%15.1
Piotroski
324.5
Int. Cover
-17.9x18.1
D/E Ratio
0.00x98.1
Current Ratio
2.43x47.1
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-7.3x25.0
P/FCF
—N/A
P/B
6.7x20.2
P/S
—N/A
Div Yield
—N/A
Momentum
23
52W High %
45%18.0
RS 6M
-29%29.9
SMA 50/200
0.89x29.4
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
-175%3.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$88M
P/E (Forward)
-2.4x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OKYO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OKYO | OKYO Pharma Limited(you) | $88M | 4 | Strong Sell |
| 4BB.L | 4basebio PLC | $110M | 10 | Strong Sell |
| SCLP.L | Scancell Holdings plc | $141M | 3 | Strong Sell |
| TLSA | Tiziana Life Sciences Ltd | $129M | 1 | Strong Sell |
| COIL.L | Coiled Therapeutics plc | $51M | 4 | Strong Sell |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $52M | 0 | Strong Sell |
| MREO | Mereo BioPharma Group plc | $50M | 12 | Strong Sell |
| POLB.L | Poolbeg Pharma PLC | $89M | 25 | Sell |
| SAR.L | Sareum Holdings plc | $63M | 19 | Strong Sell |
| IMM.L | ImmuPharma plc | $30M | 1 | Strong Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 56.0%